Bioactive Glasses As Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment

Overview

Journal Materials (Basel)

Publisher MDPI

Date 2022 Dec 23

PMID 36556893

Authors

Roger Borges

Agatha Maria Pelosine

Ana Carolina Santos de Souza

Joel Machado Jr

Giselle Zenker Justo

Lionel Fernel Gamarra

Juliana Marchi

Affiliations

Soon will be listed here.

Abstract

The treatment of bone cancer involves tumor resection followed by bone reconstruction of the defect caused by the tumor using biomaterials. Additionally, post-surgery protocols cover chemotherapy, radiotherapy, or drug administration, which are employed as adjuvant treatments to prevent tumor recurrence. In this work, we reviewed new strategies for bone cancer treatment based on bioactive glasses as carriers of cancer-targeted and other drugs that are intended for bone regeneration in conjunction with adjuvant treatments. Drugs used in combination with bioactive glasses can be classified into cancer-target, osteoclast-target, and new therapies (such as gene delivery and bioinorganic). Microparticulated, nanoparticulated, or mesoporous bioactive glasses have been used as drug-delivery systems. Additionally, surface modification through functionalization or the production of composites based on polymers and hydrogels has been employed to improve drug-release kinetics. Overall, although different drugs and drug delivery systems have been developed, there is still room for new studies involving kinase inhibitors or antibody-conjugated drugs, as these drugs have been poorly explored in combination with bioactive glasses.

Citing Articles

An In Vitro Study of the Effects of Methotrexate Loaded Biocomposite Beads on MG63 Osteoblast Cells.

Malash A, Al-Esnawy A, Ereiba K, Bakr A, Abdraboh A Sci Rep. 2025; 15(1):2231.

PMID: 39825078 PMC: 11748677. DOI: 10.1038/s41598-025-85702-y.

Targeting Bone Tumours with 45S5 Bioactive Glass.

Fellenberg J, Losch S, Arango-Ospina M, Hildenbrand N, Tripel E, Deng L Int J Mol Sci. 2024; 25(19).

PMID: 39409160 PMC: 11477169. DOI: 10.3390/ijms251910830.

Novel FeO Nanoparticles with Bioactive Glass-Naproxen Coating: Synthesis, Characterization, and In Vitro Evaluation of Bioactivity.

Valverde T, Dos Santos V, Viana P, Costa G, de Goes A, Sousa L Int J Mol Sci. 2024; 25(8).

PMID: 38673856 PMC: 11049812. DOI: 10.3390/ijms25084270.

The Impact of 45S5-Bioactive Glass on Synovial Cells in Knee Osteoarthritis-An In Vitro Study.

Platzer H, Marinescu M, Nawaz Q, Tripel E, Gantz S, Horsch A Materials (Basel). 2023; 16(24).

PMID: 38138736 PMC: 10745024. DOI: 10.3390/ma16247594.

Effects of Bioactive Glasses (BGs) on Exosome Production and Secretion: A Critical Review.

Gorgani S, Hosseini S, Wang A, Baino F, Kargozar S Materials (Basel). 2023; 16(11).

PMID: 37297327 PMC: 10254331. DOI: 10.3390/ma16114194.

References

Zhang Y, Hu M, Zhang W, Zhang X . Construction of tellurium-doped mesoporous bioactive glass nanoparticles for bone cancer therapy by promoting ROS-mediated apoptosis and antibacterial activity. J Colloid Interface Sci. 2021; 610:719-730. DOI: 10.1016/j.jcis.2021.11.122. View

Chew S, Danti S . Biomaterial-Based Implantable Devices for Cancer Therapy. Adv Healthc Mater. 2016; 6(2). DOI: 10.1002/adhm.201600766. View

Kearns L, Chapman C, Moch K, Caplan A, Watson T, McFadyen A . Gene therapy companies have an ethical obligation to develop expanded access policies. Mol Ther. 2021; 29(4):1367-1369. PMC: 8058481. DOI: 10.1016/j.ymthe.2021.03.008. View

Ernsting M, Murakami M, Roy A, Li S . Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013; 172(3):782-94. PMC: 3891171. DOI: 10.1016/j.jconrel.2013.09.013. View

Wagner M, Livingston J, Patel S, Benjamin R . Chemotherapy for Bone Sarcoma in Adults. J Oncol Pract. 2016; 12(3):208-16. DOI: 10.1200/JOP.2015.009944. View

Huo D, Jiang X, Hu Y . Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management. Adv Mater. 2019; 32(27):e1904337. DOI: 10.1002/adma.201904337. View

Polo L, Gomez-Cerezo N, Aznar E, Vivancos J, Sancenon F, Arcos D . Molecular gates in mesoporous bioactive glasses for the treatment of bone tumors and infection. Acta Biomater. 2016; 50:114-126. DOI: 10.1016/j.actbio.2016.12.025. View

Skalak R, Zargaryan S, Jain R, Netti P, Hoger A . Compatibility and the genesis of residual stress by volumetric growth. J Math Biol. 1996; 34(8):889-914. DOI: 10.1007/BF01834825. View

Ege D, Zheng K, Boccaccini A . Borate Bioactive Glasses (BBG): Bone Regeneration, Wound Healing Applications, and Future Directions. ACS Appl Bio Mater. 2022; 5(8):3608-3622. PMC: 9382634. DOI: 10.1021/acsabm.2c00384. View

10.

Zhang P, Sun F, Liu S, Jiang S . Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. J Control Release. 2016; 244(Pt B):184-193. PMC: 5747248. DOI: 10.1016/j.jconrel.2016.06.040. View

11.

Yu M, Xue Y, Ma P, Mao C, Lei B . Intrinsic Ultrahigh Drug/miRNA Loading Capacity of Biodegradable Bioactive Glass Nanoparticles toward Highly Efficient Pharmaceutical Delivery. ACS Appl Mater Interfaces. 2017; 9(10):8460-8470. DOI: 10.1021/acsami.6b13874. View

12.

Zahavi D, Weiner L . Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020; 9(3). PMC: 7551545. DOI: 10.3390/antib9030034. View

13.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

14.

Maeda H, Matsumura Y . Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 1989; 6(3):193-210. View

15.

Mahoney L, Csima A . Clinical screening for breast cancer. N Engl J Med. 1982; 306(9):546. DOI: 10.1056/NEJM198203043060916. View

16.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

17.

Stylianopoulos T, Martin J, Chauhan V, Jain S, Diop-Frimpong B, Bardeesy N . Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A. 2012; 109(38):15101-8. PMC: 3458380. DOI: 10.1073/pnas.1213353109. View

18.

Dosio F, Brusa P, Cattel L . Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel). 2011; 3(7):848-83. PMC: 3202854. DOI: 10.3390/toxins3070848. View

19.

Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux J, Benoit J . Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A. 2006; 78(3):620-8. DOI: 10.1002/jbm.a.30711. View

20.

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View